Cancer Monoclonal Antibody Partnering Terms and Agreements The Cancer Monoclonal Antibody Partnering Agreements report pro...
monoclonal antibody partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dea...
chapter 2 – Trends In Cancer Monoclonal Antibody Dealmaking2.1. Introduction2.2. Cancer Monoclonal Antibody Partneri...
developmentdistributionequity Purchaseevaluationgrantjoint Venturelicensingloanmanufacturingmarketingmaterial Transferopti...
ovarian Cancerpancreatic Cancerprostate Cancerrenal Cell Carcinomanon-melanoma Skin Cancersolid Tumorsthyroid Cancer4.6. B...
Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.us...
Upcoming SlideShare
Loading in...5
×

Cancer monoclonal antibody partnering terms and agreements

101

Published on

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
101
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Cancer monoclonal antibody partnering terms and agreements"

  1. 1. Cancer Monoclonal Antibody Partnering Terms and Agreements The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to thecancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcarecompanies. Trends in cancer monoclonal antibody partnering deals Disclosed headlines, upfronts, milestones androyalties by stage of development Cancer monoclonal antibody partnering contract documents Top cancermonoclonal antibody deals by value The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to thecancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcarecompanies. The report provides an understanding and analysis of how and why companies enter cancer monoclonalantibody partnering deals. The majority of deals are discovery or development stage whereby the licenseeobtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend tobe multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report alsoincludes antibody-drug conjugate deals and alliances. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insightinto the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms ofhow payments are triggered – contract documents provide this insight where press releases do not. This report contains over 1,000 links to online copies of actual cancer monoclonal antibody deals and whereavailable, contract documents as submitted to the Securities Exchange Commission by companies and theirpartners. Contract documents provide the answers to numerous questions about a prospective partner’sflexibility on a wide range of important issues, many of which will have a significant impact on eachparty’s ability to derive value from the deal. The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking andbusiness activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancermonoclonal antibody dealmaking since 2007, including details of disclosed headline, upfront, milestone androyalty terms. Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2007. Deals are listed byheadline value. Where the deal has an agreement contract published at the SEC a link provides online accessto the contract. Chapter 4 provides a comprehensive and detailed review of cancer monoclonal antibody partnering dealssigned and announced since 2007, and where available, a contract document is available in the public domain.The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D,co-promotion, licensing etc), and specific oncology therapy focus. Each deal title links via Weblink to anonline version of the deal record and where available, the contract document, providing easy access to eachcontract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancerCancer Monoclonal Antibody Partnering Terms and Agreements
  2. 2. monoclonal antibody partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in theresearch, development and commercialization of cancer monoclonal antibody technologies and products. Report scope Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depthunderstanding and access to cancer monoclonal antibody trends and structure of deals entered into by leadingcompanies worldwide. Cancer Monoclonal Antibody Partnering Agreements includes: Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2007 Analysis of cancermonoclonal antibody deal structure Access to headline, upfront, milestone and royalty data Access to over 500cancer monoclonal antibody deal records The leading cancer monoclonal antibody deals by value since 2007Includes antibody-drug conjugates deals and alliances since 2007 In Cancer Monoclonal Antibody Partnering Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific oncologytherapy target Monoclonal antibody type Each deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand. The Cancer Monoclonal Antibody Partnering Agreements report provides comprehensive access to availabledeals and contract documents for over 1,000 cancer monoclonal antibody deals. Analyzing actual contractagreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partnercompany? What exclusivity is granted? What is the payment structure for the deal? How aresales andpayments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRshandled and owned? Who is responsible for commercialization? Who is responsible for development, supply,and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Underwhat conditions can the deal be terminated? What happens when there is a change of ownership? Whatsublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the companyinsist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law? Benefits: In-depth understanding ofcancer monoclonal antibody deal trends since 2007 Access to headline, upfront, milestone and royalty dataAcces to the structure of cancer monoclonal antibody agreements with numerous real life case studiesComprehensive access to over 1,000 actual cancer monoclonal antibody deals entered into by theworld’s biopharma companies Insight into the terms included in a cancer monoclonal antibodyagreement, together with real world clause examples Understand the key deal terms companies have agreed inprevious deals Undertake due diligence to assess suitability of your proposed deatable Of Contentsexecutive Summarychapter 1 – IntroductionCancer Monoclonal Antibody Partnering Terms and Agreements
  3. 3. chapter 2 – Trends In Cancer Monoclonal Antibody Dealmaking2.1. Introduction2.2. Cancer Monoclonal Antibody Partnering Over The Years2.3. Bigpharma Cancer Monoclonal Antibody Dealmaking Activity2.4. Bigpharma Not Active In Cancer Monoclonal Antibody Partnering2.5. Cancer Vaccine Partnering By Deal Type2.6. Cancer Monoclonal Antibody Partnering By Stage Of Development2.7. Cancer Monoclonal Antibody Partnering By Cancer Indication2.8. Cancer Monoclonal Antibody Partnering By Antibody Type2.9. Disclosed Deal Terms For Cancer Monoclonal Antibody Partnering2.9.1 Cancer Monoclonal Antibody Partnering Headline Values2.9.2 Cancer Monoclonal Antibody Deal Upfront Payments2.9.3 Cancer Monoclonal Antibody Deal Milestone Payments2.9.4 Cancer Monoclonal Antibody Royalty Rateschapter 3 – Leading Monoclonal Antibody Cancer Deals3.1. Introduction3.2. Top Monoclonal Antibody Cancer Deals By Valuechapter 4 – Monoclonal Antibody Cancer Dealmaking Directory4.1. Introduction4.2. Company A-z4.3. By Stage Of Developmentdiscoveryformulationmarketedphase I 218phase Iiphase Iiipreclinical4.4. By Deal Typeasset Purchaseassignmentbigpharma Outlicensingco-developmentcollaborative R&dco-marketcontract Serviceco-promotioncradacross-licensingCancer Monoclonal Antibody Partnering Terms and Agreements
  4. 4. developmentdistributionequity Purchaseevaluationgrantjoint Venturelicensingloanmanufacturingmarketingmaterial Transferoptionpromotionresearchsettlementspin Outsub-licensesupplytechnology Transfertermination4.5. By Oncology Therapy Areabone Cancerbrain Cancerbreast Cancercolorectal Cancergastric Cancerhead And Neck Cancerkidney Cancerleukemiaacute Lymphoblastic Leukemiaacute Myelogenous Leukemiachronic Lymphocytic Leukemialung Cancernon Small Cell Lung Cancerlymphomahodgkins Lymphomanon Hodgkins Lymphomamelanomamesotheliomametastasesbone Metastasesmultiple MyelomaneuroblastomaCancer Monoclonal Antibody Partnering Terms and Agreements
  5. 5. ovarian Cancerpancreatic Cancerprostate Cancerrenal Cell Carcinomanon-melanoma Skin Cancersolid Tumorsthyroid Cancer4.6. By Antibody Typemonoclonal Antibodieschimeric Mabhumanized Mabhuman Mabmurine Mabchapter 5 –partnering Resource Center5.1. Online Partnering5.2. Partnering Events5.3. Further Reading On Dealmakingappendicesappendix 1 – Deal Type Definitionsappendix 2 – Example Monoclonal Antibody Cancer Partnering Agreementabout Wildwood Venturescurrent Partneringcurrent Agreementscurrent Reportsrecent Report Titles From Currentpartneringorder Form – Reportsorder Form – ReportsAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Cancer Monoclonal Antibody Partnering Terms and Agreements
  6. 6. Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Cancer Monoclonal Antibody Partnering Terms and Agreements

×